July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
The Uni-Nephrectomized SDT Fatty Rat, a novel Type 2 diabetic model of Diabetic Nephropathy, develops features of diabetic retinopathy over 10 weeks
Author Affiliations & Notes
    Iris Pharma, La Gaude, France
  • Virginie Mauro
    Iris Pharma, La Gaude, France
  • Nicolas Cimbolini
    Iris Pharma, La Gaude, France
  • Masami Shinohara
    CLEA Japan Inc., Tokyo, Japan
  • Emmanuel Brousseau
  • Takeshi Ohta
    Biological/Pharmacological Research Laboratories, JAPAN TOBACCO INC, Osaka, Japan
  • Yasushi Kageyama
    CLEA Japan Inc., Tokyo, Japan
  • Laurence Feraille
    Iris Pharma, La Gaude, France
  • Thierry Sulpice
  • Footnotes
    Commercial Relationships   FRANCOIS BRIAND, PHYSIOGENEX (E); SOPHIE ANTONELLI, Iris Pharma (E); Virginie Mauro, Iris Pharma (E); Nicolas Cimbolini, Iris Pharma (E); Masami Shinohara, CLEA Japan Inc (E); Emmanuel Brousseau, PHYSIOGENEX (E); Takeshi Ohta, JAPAN TOBACCO INC (E); Yasushi Kageyama, CLEA Japan Inc (E); Laurence Feraille, Iris Pharma (E); Thierry Sulpice, PHYSIOGENEX (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3573. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      FRANCOIS BRIAND, SOPHIE ANTONELLI, Virginie Mauro, Nicolas Cimbolini, Masami Shinohara, Emmanuel Brousseau, Takeshi Ohta, Yasushi Kageyama, Laurence Feraille, Thierry Sulpice; The Uni-Nephrectomized SDT Fatty Rat, a novel Type 2 diabetic model of Diabetic Nephropathy, develops features of diabetic retinopathy over 10 weeks
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):3573.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Animal models of spontaneous diabetes are still needed to mimic human diabetic retinopathy. We recently developed a novel model of diabetic nephropathy using the uni-nephrectomized Spontaneously Diabetic Torii (SDT) fatty rat. Fed a salt rich diet, this hypertensive/obese/type 2 diabetic rat develops advanced renal glomerulosclerosis, inflammation and fibrosis, and a >50% glomerular filtration rate decline within 10 weeks. Here we investigated whether this rat model would also develop features of diabetic retinopathy.

Methods : Two groups of 6-week old, male, Sprague Dawley (SD, control) rats and SDT fatty rats (n=10 per group) underwent unilateral nephrectomy. After a 1-week recovery period, rats were fed for 10 weeks a chow diet with 0.3% salt in drinking water (i.e. from 7 weeks to 17 weeks of age). Diabetic retinopathy was evaluated in terms of i) retinal function by electroretinogram and oscillatory potentials, ii) integrity of blood-retinal barrier by albumin–Evans blue complex leakage, iii) microscopy histopathologic studies by glial fibrillary acidic protein IHC.

Results : One week after nephrectomy, SDT fatty rats showed a diabetic phenotype, with elevated blood glucose levels (597 ± 13 vs. 120 ± 3 mg/dL in control rats, p<0.001) that sustained to 17 weeks of age. Ocular examination indicated no lens opacity in control rats, but a progressive mild to severe cataract in SDT fatty rats between 12 and 17 weeks of age. Retinal neurologic dysfunction began at 12 weeks of age in SDT fatty rat: compared to control rats, A- and B-wave amplitudes during standard scotopic ERG recording were significantly reduced, with significant peak delay in implicit times of oscillatory potentials. At the 17th week of age, Müller cells activation (measured by GFAP immunostaining) was increased in SDT fatty rats as compared to control, indicating reactive gliosis in retina. Evans blue retinal flat-mount of uni-nephrectomized SDT fatty rat also showed vessel dilatation and tortuosity at the 17th week of age without any evidence of retinal vascular permeability.

Conclusions : Uni-nephrectomized SDT fatty rats develop features of diabetic retinopathy in parallel with diabetic nephropathy. Our original data set suggests that this rat model is suitable to evaluate the effects of drugs on these type 2 diabetes co-morbidities.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.